Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

E. Perl, Alexander; Martinelli, Giovanni; E. Cortes, Jörge; Neubauer, Andreas; Berman, Ellin; Paolini, Stefania; Montesinos, Pau; R. Baer, Maria; A. Larson, Richard; Üstün, Celalettin; Fabbiano, Francesco; P. Erba, Harry; Di Stasi, Antonio; K. Stuart, Robert; L. Olin, Rebecca; Kasner, Margaret; Ciceri, Fabio; Chou, Wen‐Chien; A. Podoltsev, Nikolai; Récher, Christian; Yokoyama, Hisayuki; Hosono, Naoko; Yoon, Sung‐Soo; Lee, Je‐Hwan; S. Pardee, Timothy; T. Fathi, Amir; Liu, Chaofeng; Hasabou, Nahla; Liu, Xuan; Bahceci, Erkut; J. Levis, Mark

doi:10.1056/nejmoa1902688

Public

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML

Published in New England Journal of Medicine • Oct 30, 2019

Authors:

Alexander E. Perl

Giovanni Martinelli

Jörge E. Cortes

Abstract

BACKGROUND: -mutated AML. METHODS: -mutated AML in a 2:1 ratio to receive either gilteritinib (at a dose of 120 mg per day) or salvage chemotherapy. The two primary end points were overall survival and the percentage of patients who had complete remission with full or partial hematologic recovery. S...

Subject

Medicine

Refractory (planetary science)

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!